- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy with MEKi-EGFRi, combination therapy with MEKi.
- Other · Drug
- Lead sponsor
- Mandana Kamgar, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 29
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Overactive Bladder
- Interventions
- Retrospective chart review
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Communication Research
- Interventions
- Med Wise Rx
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Eau Claire, Wisconsin • Greendale, Wisconsin • Kenosha, Wisconsin + 1 more
- Conditions
- Peer Review, Research
- Interventions
- Intravenous fentanyl citrate, Duragesic®, Mylan generic fentanyl
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Epilepsies, Myoclonic, Drug Resistant Epilepsy
- Interventions
- Lorcaserin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- Advanced Cancer
- Interventions
- Not listed
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COVID-19
- Interventions
- No intervention
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hospices, Poly Pharmacy, Deprescriptions, Caregivers, Palliative Care, Prescription Drug Overuse, Interdisciplinary Communication
- Interventions
- NIA Medication Management - Active Comparator, STOPPFrail (Screening Tool of Older Persons Prescriptions), "Discontinuing Medication Appropriately" and "Understanding the Art of Communication about Deprescribing", "Key Approaches to Support Informal Family Caregivers in Managing Medications"
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 65 Years to 110 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Danvers, Massachusetts
- Conditions
- Prescribing Patterns, Physician, Physician's Practice Patterns, Drug Utilization Review
- Interventions
- Algorithmic Defaulting (Indication-Based Default), Active Physician Choice
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- Lidocaine 5% patch, Lidocaine hydrochloride, Lidoderm 5% patch
- Drug
- Lead sponsor
- Nicole K Brogden
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome, COVID Long-Haul
- Interventions
- Cognivue
- Device
- Lead sponsor
- Cognivue, Inc.
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Irvine, California • Visalia, California • Boca Raton, Florida + 1 more
- Conditions
- Contraception
- Interventions
- DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®
- Drug
- Lead sponsor
- FHI 360
- Other
- Eligibility
- 18 Years to 29 Years · Female only
- Enrollment
- 916 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone intravitreal implant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Intellectual Disability, Mild, Intellectual Disability, Mild to Moderate, Developmental Disability
- Interventions
- Cheek swab for PGx testing, Medication safety review
- Other
- Lead sponsor
- GalenusRx, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Montverde, Florida • The Bronx, New York
- Conditions
- Polypharmacy
- Interventions
- interdisciplinary polypharmacy clinic visit
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Deprescribing
- Interventions
- medication review
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Renal Cell Carcinoma
- Interventions
- Axitinib, Avelumab, Pembrolizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Contraception
- Interventions
- Medroxyprogesterone acetate
- Drug
- Lead sponsor
- FHI 360
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Drug-Induced Liver Injury
- Interventions
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,299,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- Many Locations, Delaware
- Conditions
- Medication Review
- Interventions
- Medication review software with pictures
- Other
- Lead sponsor
- Blake Lesselroth
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Pharmacogenetics, Pharmacogenomic Drug Interaction
- Interventions
- Pharmacist Personalized Medication Review (PMR), Discussion of Pharmacogenomic results during the PMR
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ebola Virus Disease, Marburg Virus Disease
- Interventions
- cAd3-Marburg, cAd3-EBO-S
- Biological
- Lead sponsor
- Albert B. Sabin Vaccine Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Healthy
- Interventions
- Transderm Scop®, Intravenous scopolamine hydrobromide
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Pharmacogenetics, Depression - Major Depressive Disorder, Pharmacogenomic Drug Interaction, Community Pharmacy Services
- Interventions
- Comprehensive medication management with PGx testing results, Usual Care
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania